This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Jefferies Reaffirms Their Buy Rating on Option Care Health (OPCH)
Jefferies analyst maintained a Buy rating on Option Care Health today and set a price target of $43.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Jefferies, Option Care Health also received a Buy from TipRanks – xAI’s xAi Medical – Care Facilities in a report issued today. However, on the same day, TD Cowen maintained a Hold rating on Option Care Health (NASDAQ: OPCH).
Based on Option Care Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.47 billion and a net profit of $58.5 million. In comparison, last year the company earned a revenue of $1.35 billion and had a net profit of $60.13 million
Read More on OPCH:
Disclaimer & DisclosureReport an Issue
- Option Care Health price target raised to $38 from $36 at Deutsche Bank
- Buy Rating Maintained as Stelara Headwind Fades and Core Profitability Remains Stable
- Option Care Health reports Q4 adjusted EPS 46c, consensus 47c
- Option Care Health sees FY26 adjusted EPS $1.82-$1.92, consensus $1.87
- OPCH Upcoming Earnings Report: What to Expect?
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
